Public Employees Retirement System of Ohio Acquires 2,407 Shares of Quest Diagnostics Incorporated $DGX

Public Employees Retirement System of Ohio increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 3.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,849 shares of the medical research company’s stock after buying an additional 2,407 shares during the period. Public Employees Retirement System of Ohio’s holdings in Quest Diagnostics were worth $13,101,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DGX. Moneta Group Investment Advisors LLC increased its position in Quest Diagnostics by 3.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock valued at $241,000 after acquiring an additional 50 shares during the period. HB Wealth Management LLC grew its stake in shares of Quest Diagnostics by 0.5% in the fourth quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock worth $1,960,000 after purchasing an additional 58 shares during the last quarter. Ossiam grew its stake in shares of Quest Diagnostics by 6.1% in the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock worth $202,000 after purchasing an additional 61 shares during the last quarter. Independent Advisor Alliance increased its holdings in Quest Diagnostics by 1.6% in the fourth quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after purchasing an additional 66 shares during the period. Finally, Checchi Capital Advisers LLC raised its position in Quest Diagnostics by 5.6% during the 4th quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock worth $230,000 after purchasing an additional 70 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

Insider Activity at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. This trade represents a 37.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at $25,708,601.22. This represents a 7.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by insiders.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $228.05 on Monday. The business has a 50-day moving average price of $203.23 and a two-hundred day moving average price of $197.76. Quest Diagnostics Incorporated has a 1-year low of $165.78 and a 1-year high of $237.78. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The company has a market cap of $25.17 billion, a P/E ratio of 24.21, a PEG ratio of 2.61 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the business earned $2.62 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 11.17 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were paid a $0.86 dividend. The ex-dividend date of this dividend was Wednesday, July 8th. This represents a $3.44 annualized dividend and a yield of 1.5%. Quest Diagnostics’s payout ratio is 36.52%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Mizuho upped their price target on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Friday. Wall Street Zen downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research note on Thursday. Barclays increased their target price on shares of Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, UBS Group restated a “neutral” rating and set a $232.00 price target on shares of Quest Diagnostics in a report on Friday. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and an average price target of $231.73.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.